Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction

References

• Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998; 9: 395–404
   PubMed Web of Science ®Google Scholar
• Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157–68
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows SR. Role of cytotoxic T-lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19–48
   PubMed Web of Science ®Google Scholar
• Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, et al. Epstein-Barr virus associated B -cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–43
   PubMed Web of Science ®Google Scholar
• Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, et al. Secondary cancers after bone marrow transplantation for leukaemia or aplastic anaemia. N Engl J Med 1989; 321: 784–9
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–49
   PubMed Web of Science ®Google Scholar
• Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517–25
   PubMed Web of Science ®Google Scholar
• Meijer E, Spijkers S, Moschatsis S, Boland GJ, Thijsen SFT, van Loon AM, et al. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation?. Transpl Infect Dis 2005; 7: 4–10
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–16
   PubMed Web of Science ®Google Scholar
• Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–8
   PubMed Web of Science ®Google Scholar
• Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–9
   PubMed Web of Science ®Google Scholar
• Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, et al. B-cell lymphoproliferative disorders following haematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251–8
   PubMed Web of Science ®Google Scholar
• Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–39
   PubMed Web of Science ®Google Scholar
• Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, et al. Post-transplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462–7
   PubMed Web of Science ®Google Scholar
• van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–9
   PubMed Web of Science ®Google Scholar
• Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–61
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–8
   PubMed Web of Science ®Google Scholar
• Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Dilloo D, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor post-transplant lymphoproliferative disease. J Clin Microbiol. 2002; 40: 351–8
   PubMed Web of Science ®Google Scholar
• Gross TG, Loechelt BJ. Epstein-Barr virus associated disease following blood or marrow transplant. Pediatr Transplant 2003; 7: 44–50
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145–55
   PubMed Web of Science ®Google Scholar
• Enbom M, Strand A, Falk KI, Linde A. Detection of Epstein-Barr virus, but not human herpes virus 8, DNA in cervical secretions from Swedish women by real time polymerase chain reaction. Sex Transm Dis 2001; 28: 300–6
   PubMed Web of Science ®Google Scholar
• Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 2002; 8: 432–8
   PubMed Web of Science ®Google Scholar
• Clave E, Agbalika F, Bajzik V, de Latour RP, Trillard M, Rabian C, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76–84
   PubMed Web of Science ®Google Scholar
• Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, et al. The real time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–33
   PubMed Web of Science ®Google Scholar
• Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97–102
   PubMed Web of Science ®Google Scholar
• Lange A, Klimczak A, Dlubek D, Dybko J. B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after haematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transplant Proc 2003; 35: 3093–5
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001; 98: 2942–7
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Antilymphocyte/thymocyte globulin for graft-versus-host disease prophylaxis: efficacy and side-effects. Bone Marrow Transplant 2005; 35: 225–31
   PubMed Web of Science ®Google Scholar
• Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M, Burchardt A, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated haematopoietic stem cell transplantation for acute myeloid leukaemia: results from the multicentre German cooperative study group. Bone Marrow Transplant 2005; 35: 1011–8
   PubMed Web of Science ®Google Scholar
• Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, ter Veer A, Li X, Niland JC, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782–5
   PubMed Web of Science ®Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for post-transplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076–88
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–91
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–55
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T-cells. Blood 2000; 95: 807–14
   PubMed Web of Science ®Google Scholar
• Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–8
   PubMed Web of Science ®Google Scholar
• van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–9
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191–6
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–95
   PubMed Web of Science ®Google Scholar